BioDlink International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat metastatic colorectal cancer; advanced, metastatic or recurrent non-small cell lung cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer; fallopian tube cancer or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatment of glioblastoma and anaplastic astrocytoma. In addition, the company develops TAB014 a bevacizumab ophthalmic drug for the treatment of wet age-related macular degeneration (wAMD). Further, it engages in contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business; license-out of self-developed biological drugs; and business development, investing, and marketing promotion activities. The company was formerly known as TOT BIOPHARM International Company Limited and changed its name to BioDlink International Company Limited in July 2025. BioDlink International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China. BioDlink International Company Limited operates as a subsidiary of WuXi XDC Cayman Inc.
Frequently asked questions
What sector does Tot Biopharm International Co Ltd (1875) operate in?
Tot Biopharm International Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Tot Biopharm International Co Ltd (1875) current stock price?
As of the latest data, Tot Biopharm International Co Ltd stock price is HK$3.82, with a previous close of HK$3.77. Tot Biopharm International Co Ltd gained HK$0.05 in the last trading session, representing a 1.33% increase.
What is Tot Biopharm International Co Ltd (1875) current market capitalization?
Tot Biopharm International Co Ltd market cap is approximately 2.77 billion.
What is Tot Biopharm International Co Ltd (1875) EBITDA?
Tot Biopharm International Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -14.03 million.
Does Tot Biopharm International Co Ltd (1875) pay dividends?
No. Tot Biopharm International Co Ltd does not pay a dividend.
What is Tot Biopharm International Co Ltd (1875) beta (volatility) score?
Tot Biopharm International Co Ltd has a beta of -0.111, indicating lower volatility than the overall market.
